ALNYLAM PHARMACEUTICALS, INC. 10-Q filing
Filed 2026-07-30 · Report date 2026-06-30 · 2026
Filing metadata
- Accession number
- 0001178670-26-000062
- Form type
- 10-Q
- CIK
- 0001178670
- Primary document
- https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for ALNYLAM PHARMACEUTICALS, INC..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $2.5B | - | - |
| Cost Of Revenue | $505.8M | - | - |
| Operating Income | $500.1M | - | - |
| Net Income | $370.5M | - | - |
| Eps Basic | 2.78 | - | - |
| Eps Diluted | 2.71 | - | - |
| Cash And Equivalents | $1.7B | - | - |
| Total Assets | $5.6B | - | - |
| Total Liabilities | $4.2B | - | - |
| Shareholders Equity | $1.4B | - | - |
| Operating Cash Flow | $397.2M | - | - |
| Capital Expenditures | $56.5M | - | - |